Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quanterix Corporation (NASDAQ: QTRX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI‑supported context to help interpret them. As a life sciences and testing laboratories company focused on ultra-sensitive biomarker detection and spatial biology, Quanterix uses its SEC reports to describe its financial performance, corporate transactions, and governance decisions.
Key documents available here include Form 10‑K annual reports and Form 10‑Q quarterly reports, which outline revenue from product sales, service and other revenue, collaboration and license revenue, and grant revenue. These filings also discuss cost of goods sold, research and development expenses, selling, general and administrative expenses, and the use of non‑GAAP measures such as adjusted EBITDA, adjusted gross margin, and adjusted cash usage. AI summaries can highlight how these metrics relate to Quanterix’s Simoa platforms, Accelerator Laboratory services, and the integration of Akoya Biosciences.
Frequent Form 8‑K current reports document material events. Recent examples include announcements of quarterly financial results, the completion and pro forma impact of the Akoya acquisition, shareholder votes on declassifying the Board and eliminating supermajority voting requirements, and changes in Board composition. Our tools surface the main points of each 8‑K so readers can quickly understand what changed and why it matters for QTRX.
Investors can also review proxy statements referenced in the filings for details on director elections, executive compensation proposals, and governance changes, as well as any Form 4 insider transaction reports that may be filed separately. Real‑time updates from EDGAR ensure that new filings appear promptly, while AI‑generated explanations help translate technical accounting and legal language into more accessible summaries.
Use this page to explore Quanterix’s historical and current SEC filings, compare reporting periods, and understand how financial results, acquisitions, and governance actions are reflected in official disclosures.
Quanterix Corp Chief Operating Officer Michael Francis Miller exercised restricted stock units into common shares and had a portion withheld for taxes. On March 31, 2026, he converted 229 restricted stock units, which convert to common stock on a one-for-one basis, into the same number of common shares at a stated price of $0.00 per share.
To cover tax obligations, 69 common shares were disposed of through tax-withholding transactions at $3.52 per share, leaving him with a net increase of 160 common shares. Following these transactions, Miller directly owned 31,431 shares of Quanterix common stock. The restricted stock units exercised were part of prior grants from April 7, 2022 and September 23, 2022 that vest over time.
The Vanguard Group amended its Schedule 13G/A to report zero beneficial ownership of Quanterix Corp common stock. The filing (Amendment No. 2) explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report holdings separately. The schedule states Amount beneficially owned: 0 and Percent of class: 0%. The amendment is signed by Ashley Grim on 03/27/2026.
Quanterix Corp Chief Legal Officer Daniel Char has reported initial equity holdings. The filing shows grants received on January 15, 2026 of 33,962 restricted stock units tied to common stock and 113,171 stock options to buy common shares at an exercise price of $7.95 per share. Both awards vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments, creating a multi-year incentive structure aligned with continued service.
Quanterix Corp’s Chief Operating Officer Michael Francis Miller reported routine equity compensation activity. On March 15, 2026, multiple restricted stock unit awards converted into common stock, with derivative exercises totaling 1,558 shares according to the filing’s transaction summary.
To cover related tax obligations, 549 common shares were withheld at a price of $4.72 per share under code F transactions, which are tax-withholding dispositions rather than market sales. Following these transactions, Miller directly holds 31,271 shares of Quanterix common stock.
Quanterix Corp Chief Operating Officer Michael Francis Miller filed an initial ownership report showing his equity-based holdings in the company. As of February 23, 2026, he holds 74,905 Performance Stock Units granted on February 15, 2026, which vest in four equal annual installments after meeting performance conditions under the 2026 Employee Equity Guidelines.
He also holds multiple Restricted Stock Unit awards, including 74,905 RSUs granted on February 15, 2026 that vest 25% per year for four years, plus earlier RSU grants from 2022–2025 with monthly vesting schedules after the first anniversary. In addition, he has several option grants to buy Common Stock at exercise prices between $8.4300 and $54.0400 per share, with expirations between July 28, 2031 and February 4, 2035, and directly owns 30,262 shares of Common Stock.
Quanterix Corp Chief Financial Officer Vandana Sriram reported routine equity compensation activity involving restricted stock units that convert into common stock on a one-for-one basis. On March 15, 2026, she exercised RSUs covering 1,833 common shares in total through derivative exercises.
To satisfy tax obligations, 645 common shares were withheld and disposed of at $4.72 per share, with the remaining shares added to her direct holdings. Following these transactions, she directly owned 27,428 shares of Quanterix common stock. The RSUs stem from prior grants of 12,624 units on August 21, 2023, 24,675 units on February 2, 2024, and 50,712 units on February 4, 2025, each vesting over time with an initial 25% cliff and subsequent monthly installments.
Quanterix Corporation outlines how it is building a biomarker and spatial biology platform spanning research to diagnostics. The company now has over 2,500 instruments installed and more than 6,200 scientific publications citing its Simoa and Spatial Biology technologies in neurology, oncology, immunology, and inflammation.
In 2025 Quanterix acquired Akoya Biosciences, adding high-plex tissue imaging, and Emission, Inc., securing bead manufacturing and a mid-plex platform. It is pushing into Alzheimer’s diagnostics with its LucentAD Complete multi-marker blood test, which received a $897 Medicare reimbursement rate, and a multi-analyte blood test that has FDA Breakthrough Device Designation and a submitted 510(k) for detecting amyloid pathology.
The report also highlights governance and leadership changes, including new directors, a new CEO, and a cooperation agreement with Kent Lake Partners, as Quanterix positions its technology and CLIA-certified laboratory services for broader diagnostic use.
Quanterix reported fourth quarter and full-year 2025 results and issued its 2026 outlook. Q4 2025 revenue was $43.9 million, up from $35.2 million, while full-year revenue was $138.9 million versus $137.4 million in 2024. GAAP gross margin fell to 46.8% for 2025 from 60.5%, and the company recorded a net loss of $107.2 million, wider than $38.5 million a year earlier. Adjusted EBITDA loss was $44.9 million.
Quanterix ended 2025 with $121.6 million in cash, cash equivalents, marketable securities and restricted cash and has implemented $74 million of an $85 million cost-synergy target tied to the Akoya acquisition. The company submitted a 510(k) to the FDA for its multi-analyte Alzheimer’s blood test and CMS set a $897 reimbursement rate for the LucentAD Complete test. For 2026, Quanterix guides to revenue of $169–$174 million, GAAP gross margin of 45–49%, adjusted gross margin of 49–53%, and expects to reach cash flow breakeven in the second half of 2026 and exit the year with about $100 million in cash and no debt.
Quanterix Corp’s chief financial officer, Vandana Sriram, reported equity award and related tax transactions. The CFO received grants of 74,905 performance stock units and 74,905 restricted stock units at a stated price of $0 per unit. Footnotes explain that PSUs vest based on performance conditions and then in four equal annual installments starting on the first anniversary of the grant date, while the new RSU award also vests in four equal annual installments.
The filing also shows exercises of previously granted restricted stock units into common stock, along with share dispositions to cover tax obligations. Specifically, 514 and 263 RSUs were converted into common stock, and 179 and 92 common shares were withheld at $5.74 per share to satisfy tax liabilities. After these transactions, the CFO directly held 26,240 shares of Quanterix common stock.
Quanterix Corp. received an amended Schedule 13G/A showing that a group of affiliated Ameriprise entities collectively report beneficial ownership of 4,996,073 shares of Quanterix common stock, representing 10.7% of the class as of 12/31/2025.
The filing lists Ameriprise Financial, Inc. and multiple UK- and Luxembourg-based subsidiaries with shared voting and dispositive power over these shares. The Ameriprise entities state the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Quanterix.